No article text was recorded for this version.
off-target tracer binding
Version 2 of 233 papers63 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
- Blog: Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue
- Blog: THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report
- Blog: Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases
- Blog: In vivo quantification of neurofibrillary tangles with [18F]MK-6240
- Blog: 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
- Blog: Tau Positron Emission Tomography and Neurocognitive Function Among Former Professional American-Style Football Players
- Blog: The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
- Blog: Voxelwise Relationships Between Distribution Volume Ratio and Cerebral Blood Flow: Implications for Analysis of β-Amyloid Images
- Blog: Synthesis of novel neutrophil-specific imaging agents for Positron Emission Tomography (PET) imaging
- Blog: Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
- Blog: Quantifying extracerebral off‐target contamination in [ <sup>18</sup> F]MK6240 PET imaging using compartmental modeling
- Blog: One-Year Longitudinal Changes in Tau Accumulation on [<sup>18</sup>F]PI-2620 PET in the Alzheimer Spectrum
- Blog: 18F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
- Blog: Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer’s disease differ according to disease severity and amyloid positivity
- Blog: PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714
- Blog: CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody
- Blog: Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease
- Blog: The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
- Blog: TSPO-PET reveals higher inflammation in white matter disrupted by paramagnetic rim lesions in multiple sclerosis
- Blog: PET-measured human dopamine synthesis capacity and receptor availability predict trading rewards and time-costs during foraging
- Blog: A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development
- Blog: In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain
- Blog: High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes
- Blog: Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
- Blog: Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971
- Blog: Synthesis and characterization of 5-(2-fluoro-4-[ <sup>11</sup> C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2 <i>H</i> -pyrano[2,3- <i>b</i> ]pyridine-7-carboxamide as a PET imaging ligand for metabotropic glutamate receptor 2
- Blog: 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model
- Blog: Improved amyloid burden quantification with nonspecific estimates using deep learning
- Blog: PSMA-11–Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer
- Blog: Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography
- Blog: PET of c-Met in Cancer with <sup>64</sup>Cu-Labeled Hepatocyte Growth Factor
- Blog: Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_off_target_tracer_binding_f562bd0c,
title = {off-target tracer binding},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/off-target-tracer-binding/rdr_f562bd0c08a14fc09166a4bd12c26447},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 2, frozen text):
@misc{lacuna_off_target_tracer_binding_f562bd0c_v2,
title = {off-target tracer binding},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/off-target-tracer-binding/rdr_f562bd0c08a14fc09166a4bd12c26447/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-19},
}